NASDAQ:IPHA

Innate Pharma (IPHA) Stock Price, News & Analysis

Innate Pharma logo
$0.87 -0.07 (-7.76%)
As of 02:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Innate Pharma Stock (NASDAQ:IPHA)

Advanced

Key Stats

Today's Range
$0.83
▼
$0.92
50-Day Range
$0.94
▼
$2.01
52-Week Range
$0.83
▼
$2.71
Volume
16,888 shs
Average Volume
76,497 shs
Market Capitalization
$96.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.67
Consensus Rating
Moderate Buy

Company Overview

Innate Pharma is a clinical-stage biotechnology company based in Marseille, France. It develops immunotherapies for cancer, with research focused on harnessing the body’s innate immune system to recognize and attack tumor cells.

The company’s work includes antibody-based treatments and cell therapies, with investigational candidates being studied for blood cancers and other malignancies. Its pipeline includes lacutamab, an antibody candidate targeting KIR3DL2, and programs developed with pharmaceutical partners.

Innate Pharma conducts research and clinical development in France and works with international partners, including companies such as AstraZeneca and Sanofi. Its activities are centered on advancing investigational therapies rather than marketing a broad portfolio of approved medicines.

AI Generated. May Contain Errors.

Innate Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

IPHA MarketRank™: 
2.49965729952 of 5 stars

Innate Pharma scored higher than 50% of companies evaluated by MarketBeat, and ranked 486th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Innate Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Innate Pharma has a consensus price target of $5.67, representing about 573.0% upside from its current price of $0.84.

  • Amount of Analyst Coverage

    Innate Pharma has only been the subject of 4 research reports in the past 90 days.

  • Read more about Innate Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Innate Pharma are expected to grow in the coming year, from ($0.53) to ($0.45) per share.

  • Percentage of Shares Shorted

    0.16% of the float of Innate Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Innate Pharma has a short interest ratio ("days to cover") of 8.92.
  • Change versus previous month

    Short interest in Innate Pharma has recently decreased by 2.86%, indicating that investor sentiment is improving.
  • Dividend Yield

    Innate Pharma does not currently pay a dividend.

  • Dividend Growth

    Innate Pharma does not have a long track record of dividend growth.

  • News Sentiment

    Innate Pharma has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Innate Pharma this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Innate Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Innate Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    31.89% of the stock of Innate Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    0.16% of the stock of Innate Pharma is held by institutions.

  • Read more about Innate Pharma's insider trading history.
Receive IPHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IPHA Stock News Headlines

Innate Pharma stock tumbles after phase 1 trial data
Beyond NVDA: The World’s Next #1 Company?
This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's. A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all.tc pixel
Innate Pharma S.A. (IPHA) Q3 2026 Earnings Call Transcript
See More Headlines

IPHA Stock Analysis - Frequently Asked Questions

Innate Pharma's stock was trading at $1.75 at the beginning of 2026. Since then, IPHA shares have decreased by 51.9% and is now trading at $0.8420.

Innate Pharma (IPHA) raised $80 million in an initial public offering on Thursday, October 17th 2019. The company issued 10,700,000 shares at $7.50 per share. Citigroup, SVB Leerink and Evercore ISI served as the underwriters for the IPO.

Shares of IPHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Innate Pharma investors own include Tesla (TSLA), Viking Therapeutics (VKTX), Block (XYZ), Voyager Therapeutics (VYGR), NIO (NIO), Pfizer (PFE) and Advanced Micro Devices (AMD).

Company Calendar

Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IPHA
CIK
1598599
Fax
N/A
Employees
163
Year Founded
1999

Price Target and Rating

High Price Target
$9.00
Low Price Target
$1.00
Potential Upside/Downside
+553.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.60
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$10.19 million
Price / Sales
9.51
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.26) per share
Price / Book
-3.33

Miscellaneous

Outstanding Shares
111,720,000
Free Float
76,092,000
Market Cap
$96.86 million
Optionable
Not Optionable
Beta
0.78

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:IPHA) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners